PARP inhibition reverses radiation resistance conferred by ETS fusions in prostate cancer. Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): Five-year (yr) overall survival (OS) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results